ATE371447T1 - Natürliche vitamin-e-zusammsetzungen mitausgezeichneter antioxidationswirksamkeit - Google Patents

Natürliche vitamin-e-zusammsetzungen mitausgezeichneter antioxidationswirksamkeit

Info

Publication number
ATE371447T1
ATE371447T1 AT03813747T AT03813747T ATE371447T1 AT E371447 T1 ATE371447 T1 AT E371447T1 AT 03813747 T AT03813747 T AT 03813747T AT 03813747 T AT03813747 T AT 03813747T AT E371447 T1 ATE371447 T1 AT E371447T1
Authority
AT
Austria
Prior art keywords
compositions
alpha
tocopherol
natural vitamin
effectiveness
Prior art date
Application number
AT03813747T
Other languages
English (en)
Inventor
Yousry Naguib
Ronald Udell
Richard Passwater
Melvin Rich
Original Assignee
Soft Gel Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soft Gel Technologies Inc filed Critical Soft Gel Technologies Inc
Application granted granted Critical
Publication of ATE371447T1 publication Critical patent/ATE371447T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03813747T 2002-12-17 2003-12-17 Natürliche vitamin-e-zusammsetzungen mitausgezeichneter antioxidationswirksamkeit ATE371447T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/321,318 US7329688B2 (en) 2002-12-17 2002-12-17 Natural vitamin E compositions with superior antioxidant potency

Publications (1)

Publication Number Publication Date
ATE371447T1 true ATE371447T1 (de) 2007-09-15

Family

ID=32507093

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03813747T ATE371447T1 (de) 2002-12-17 2003-12-17 Natürliche vitamin-e-zusammsetzungen mitausgezeichneter antioxidationswirksamkeit

Country Status (6)

Country Link
US (4) US7329688B2 (de)
EP (1) EP1572195B1 (de)
AT (1) ATE371447T1 (de)
AU (1) AU2003301069B2 (de)
DE (1) DE60316024D1 (de)
WO (1) WO2004056348A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716451B1 (en) * 1999-11-30 2004-04-06 Soft Gel Technologies, Inc. Formulation and delivery method to enhance antioxidant potency of vitamin E
AU2002327517B2 (en) * 2001-08-21 2008-04-17 Johnson & Johnson Consumer Companies, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
EP1450787A4 (de) * 2001-11-15 2006-01-25 Galileo Pharmaceuticals Inc Formulierungen und verfahren zur behandlung oder linderung von entzündlichen zuständen
JP2005532394A (ja) * 2002-07-02 2005-10-27 ガリレオ ファーマシューティカルズ， インコーポレイティド 雌性被験体における炎症性症状および／またはバイオマーカーの低減のための組成物および方法
US7329688B2 (en) * 2002-12-17 2008-02-12 Soft Gel Technologies, Inc. Natural vitamin E compositions with superior antioxidant potency
WO2005048929A2 (en) * 2003-11-13 2005-06-02 Galileo Pharmaceuticals, Inc. Plant-derived protein extract compositions and methods
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20070021497A1 (en) * 2005-07-11 2007-01-25 The Fruitful Yield Vitamin e compositions
KR101430767B1 (ko) * 2005-07-18 2014-08-19 유니버시티 오브 메사츄세츠 로웰 나노에멀젼 조성물 및 이의 제조 및 사용 방법
HUP0500975A2 (en) * 2005-10-25 2008-02-28 Arpad Tosaki Process for producing of extract of sour cherry seed, use of extract for producing of medicament and medicaments consist extract
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US10251861B2 (en) 2012-06-08 2019-04-09 Ohio State Innovation Foundation Methods for treating burn and scar injury using tocotrienol compositions
EP3510161A4 (de) 2016-08-23 2020-04-22 Akouos, Inc. Zusammensetzungen und verfahren zur behandlung von nicht altersbedingten hörschäden bei einer person
EP3541358A1 (de) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermale verabreichung von grossen wirkstoffen
BR112022016596A2 (pt) 2020-02-21 2022-11-16 Akouos Inc Composições e métodos para o tratamento de debilitação auditiva não associada à idade em um indivíduo humano

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940900A (en) 1957-09-25 1960-06-14 Eastman Kodak Co Dry vitamine e composition
US3102078A (en) 1961-01-13 1963-08-27 Eastman Kodak Co Water-dispersible vitamin preparations
US3212901A (en) 1961-06-07 1965-10-19 Eastman Kodak Co Stabilized tocopherol concentrates and process for preparing the same
US3564097A (en) 1968-04-05 1971-02-16 Louis Magid Stable multivitamin tablets containing tricalcium phosphate
US4364945A (en) 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4551332A (en) 1981-08-05 1985-11-05 Theodore Stillman Vitamin E compositions and methods
US5948769A (en) * 1984-01-28 1999-09-07 Ismail; Roshdy Agent for treating heart diseases
US4612194A (en) 1984-02-15 1986-09-16 Roshdy Ismail Anti-rheumatic agents and their use
US4711894A (en) 1986-01-16 1987-12-08 Henkel Corporation Stabilized tocopherol in dry, particulate, free-flowing form
DE3805927A1 (de) * 1988-02-25 1989-08-31 Bosch Gmbh Robert Vorrichtung zur verbesserung der gemischverteilung
US5217992A (en) 1989-10-04 1993-06-08 Bristol-Myers Squibb Company Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
FR2657526B1 (fr) 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
US5114957A (en) 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
WO1993009777A1 (en) 1991-11-22 1993-05-27 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use
US5102659A (en) * 1990-07-12 1992-04-07 Shaklee Corporation Natural antioxidant compositions
US5179122A (en) 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5545398A (en) 1993-01-13 1996-08-13 Perricone; Nicholos V. Method and compositions for topical application to the skin of tocotrienol for prevention and/or treatment of skin damage
US5376361A (en) 1993-01-13 1994-12-27 Perricone; Nicholas V. Method and compositions for topical application to the skin for prevention and/or treatment of radiation-induced skin damage
US5352696A (en) 1993-01-22 1994-10-04 Pacific Corporation Quaternary nitrogen-containing vitamin E derivatives and uses thereof
JP3651915B2 (ja) 1993-06-30 2005-05-25 財団法人神奈川科学技術アカデミー シグナル配列ペプチドをコードするｄｎａ断片の探索法及びそのためのベクター
AU4688296A (en) * 1994-12-22 1996-07-10 Henkel Corporation Tocopherol and tocotrienol compositions
US6358997B1 (en) 1995-12-22 2002-03-19 Cognis Corporation Tocopherol and tocotrienol compositions
JP2001513571A (ja) 1997-08-29 2001-09-04 ザ リセックス カンパニー インコーポレイテッド 糖尿病、高血糖症及び低血糖症の治療法
US5985344A (en) * 1997-09-02 1999-11-16 The Ricex Company Process for obtaining micronutrient enriched rice bran oil
US5997892A (en) 1997-10-09 1999-12-07 Camp; Gary Don Topical therapeutic composition for and method of treating psoriasis
US6277431B1 (en) 1998-10-14 2001-08-21 Redeem, Inc. Anticholesterolemic edible oil
US6048891A (en) 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6716451B1 (en) * 1999-11-30 2004-04-06 Soft Gel Technologies, Inc. Formulation and delivery method to enhance antioxidant potency of vitamin E
US7329688B2 (en) 2002-12-17 2008-02-12 Soft Gel Technologies, Inc. Natural vitamin E compositions with superior antioxidant potency

Also Published As

Publication number Publication date
US20060093664A1 (en) 2006-05-04
EP1572195A2 (de) 2005-09-14
WO2004056348A2 (en) 2004-07-08
US7329688B2 (en) 2008-02-12
EP1572195B1 (de) 2007-08-29
US20040116512A1 (en) 2004-06-17
US7989493B2 (en) 2011-08-02
AU2003301069B2 (en) 2010-11-18
AU2003301069A1 (en) 2004-07-14
US7449491B2 (en) 2008-11-11
US20110251274A1 (en) 2011-10-13
US20090156664A1 (en) 2009-06-18
DE60316024D1 (de) 2007-10-11
WO2004056348A3 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
DE60316024D1 (de) Natürliche vitamin-e-zusammsetzungen mitausgezeichneter antioxidationswirksamkeit
DK0977562T3 (da) Fremgangsmåder og sammensætninger til indgivelse af taxaner
TW200626132A (en) Topical nepafenac formulations
DK1802274T3 (da) Anvendelse af cannabidiol i inhibitionen af hjernetumorcellemigration
NO20040917L (no) Oftamologiske depotpreparater for periokular eller subkonjunktival administrering.
BR0210139A (pt) Composições farmacêuticas
AU2002353971A1 (en) Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
AU2002327180A1 (en) Detection and therapy of vulnerable plaque with photodynamic compounds
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
TW200505890A (en) Breast cancer-resistant protein inhibitor
SG156613A1 (en) Use of mitochondrially targeted antioxidant in the treatment of liver diseases and epithelial cancers
MXPA04006039A (es) Metodo para el tratamiento de afecciones vasculares y neuronales perifericas.
AR061707A2 (es) Metodo para el tratamiento de insuficiencias venosas cronicas utilizando un extracto de hojas de vid roja
NO20061236L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og paratyroidhoziiton
DK1562447T3 (da) Antioxidative sammensætninger
AU3287200A (en) Composition comprising isoquercetin and ascorbic acid in a sustained release form
PT1893237E (pt) Composição farmacêutica compreendendo um elastómero organopolissiloxano e um princípio activo solubilizado
DK1196174T3 (da) Diætmæssigt calcium, som et tilskud til D-vitamin-forbindelsesbehandling af multipel sclerose
MEP34308A (en) Oral formulations of cladribine
ATE361743T1 (de) Beschichtete minitabletten von venlafaxinhydrochlorid mit verlängerter freisetzung
WO2005000204A3 (en) Pancreatic cancer treatment
WO2002078690A3 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
MXPA03006477A (es) Metodo de tratamiento de diabetes tipo i.
WO2004010974A3 (en) Gelatin capsule exhibiting reduced cross-linking
DE60005548D1 (de) Zusammensetzung enthaltend einen extrakt aus perna canaliculus, methylsulfonylmethan und glucosamine und verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties